Syon Capital LLC Buys Shares of 53,469 Verve Therapeutics, Inc. (NASDAQ:VERV)

Syon Capital LLC acquired a new stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 53,469 shares of the company's stock, valued at approximately $302,000. Syon Capital LLC owned approximately 0.06% of Verve Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its holdings in Verve Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock valued at $101,000 after purchasing an additional 1,676 shares in the last quarter. Rhumbline Advisers lifted its holdings in Verve Therapeutics by 1.9% during the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock valued at $627,000 after purchasing an additional 2,093 shares in the last quarter. Arizona State Retirement System lifted its holdings in Verve Therapeutics by 15.8% during the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company's stock valued at $111,000 after purchasing an additional 2,669 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Verve Therapeutics by 5.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company's stock valued at $313,000 after purchasing an additional 2,742 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Verve Therapeutics by 5.7% during the fourth quarter. Invesco Ltd. now owns 57,140 shares of the company's stock valued at $322,000 after purchasing an additional 3,080 shares in the last quarter. 97.11% of the stock is owned by hedge funds and other institutional investors.

Verve Therapeutics Stock Performance

Shares of VERV stock traded down $0.11 on Thursday, hitting $5.57. 1,003,145 shares of the stock traded hands, compared to its average volume of 1,774,764. The firm's 50-day moving average price is $5.22 and its two-hundred day moving average price is $5.95. The stock has a market capitalization of $496.08 million, a PE ratio of -2.26 and a beta of 1.86. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. On average, equities research analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on VERV shares. Guggenheim increased their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Royal Bank of Canada cut their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Canaccord Genuity Group boosted their target price on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Finally, HC Wainwright boosted their price objective on Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, April 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.